BioCentury
ARTICLE | Emerging Company Profile

Phrixus: Healing Broken Hearts

June 29, 2009 7:00 AM UTC

Several companies have attempted to develop poloxamer 188 for a range of indications, but the compound never made it past Phase III trials. Phrixus Pharmaceuticals Inc. has found new indications for the non-ionic block copolymer based on preclinical work showing a different mechanism than its previous developers thought it had.

The newco plans to develop poloxamer 188 (P188), which it calls Carmeseal, for acute decompensated heart failure, chronic heart failure and heart failure associated with muscular dystrophy. It is targeting an IND submission in 3Q09...